Chemical inhibitors of SRPX can exert their inhibitory effects through various mechanisms by targeting different signaling pathways critical for the protein's functional role in synapse formation and neurite growth. PD98059 and U0126 are both inhibitors of the MEK enzymes within the MAPK/ERK pathway, a route crucial for synaptic plasticity and neuron differentiation, events where SRPX is known to be involved. By inhibiting MEK, these chemicals prevent the downstream activation of ERK, which is necessary for the synaptic functions associated with SRPX. Similarly, LY294002 and Wortmannin inhibit the PI3K/Akt signaling pathway, which is fundamental for neuronal survival and synaptic formation. The inhibition of PI3K by these chemicals can suppress Akt phosphorylation, thus impeding the signaling required for SRPX to play its role in neuronal health and synaptogenesis.
Further, chemicals like Rapamycin, SP600125, and SB203580 target other key pathways that indirectly inhibit SRPX function. Rapamycin inhibits mTOR, a kinase that is part of a central cell-growth and neuron regulation pathway, affecting neuron maturation where SRPX is implicated. SP600125 blocks JNK activity, which is involved in neuronal apoptosis and inflammatory responses, while SB203580 specifically inhibits p38 MAPK, disrupting signaling pathways involved in synaptic formation and plasticity, which require SRPX activity. Additionally, Src family kinases, which are implicated in neuronal differentiation and synapse formation, can be inhibited by PP2 and Dasatinib, potentially impairing SRPX function in these processes. Gefitinib targets the EGFR signaling pathway, inhibition of which can disrupt neuronal survival and plasticity, processes where SRPX is known to function. Y-27632, a ROCK inhibitor, affects cytoskeletal dynamics, thereby impeding the morphological processes where SRPX is involved. Lastly, Bisindolylmaleimide I inhibits PKC, which plays a part in regulating synaptic plasticity and neuron communication, processes that are critical for SRPX function. By targeting these various pathways, each chemical can contribute to the functional inhibition of SRPX, impacting its role in neuronal and synaptic development.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. Since SRPX is involved in synaptic formation and neurite growth, and the MAPK/ERK pathway is critical for these processes, PD98059 would inhibit SRPX function by preventing activation of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, also in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents ERK activation, thereby inhibiting downstream effects on synaptic function where SRPX plays a role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that would suppress the PI3K/Akt signaling pathway. Since PI3K/Akt is essential for synaptic formation and neuron survival, LY294002 inhibition of this pathway could lead to functional inhibition of SRPX by undermining an essential pathway for its role in synaptogenesis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, similar to LY294002, Wortmannin would inhibit the PI3K/Akt pathway. This would functionally inhibit SRPX by blocking the signaling required for its role in synaptic development and neuron survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which is part of the mTOR signaling pathway crucial for cell growth and neuron regulation. By inhibiting mTOR, Rapamycin could suppress the cellular processes essential for the functional role of SRPX in neuron maturation and synaptic plasticity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is involved in inflammatory responses and apoptosis. By inhibiting JNK, SP600125 could hinder the pathways that affect neuronal survival and synaptic plasticity, where SRPX is implicated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, which could inhibit stress-activated protein kinase signaling involved in synaptic formation and plasticity, processes that require SRPX function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor, which could block signaling pathways involved in neuronal differentiation and synapse formation, thus potentially inhibiting SRPX function in these processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Another Src family kinase inhibitor, Dasatinib could prevent Src kinase activity and thus inhibit downstream signaling cascades that may involve SRPX in synaptic modulation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR inhibitor, which would inhibit the EGFR signaling pathway. Since EGFR signaling is important for neuronal survival and plasticity, Gefitinib would functionally inhibit SRPX by hindering its role in these processes. |